Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study

Richard R. Rubin, Yong Ma, Mark Peyrot, David G. Marrero, David W. Price, Elizabeth Barrett-Connor, William C. Knowler

Research output: Contribution to journalArticle

49 Scopus citations


OBJECTIVE - To assess the association between antidepressant medicine use and risk of developing diabetes during the Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study (DPPOS). RESEARCH DESIGN AND METHODS - DPP/DPPOS participants were assessed for diabetes every 6 months and for antidepressant use every 3 months in DPP and every 6 months in DPPOS for a median 10.0-year follow-up. RESULTS - Controlled for factors associated with diabetes risk, continuous antidepressant use compared with no use was associated with diabetes risk in the placebo (adjusted hazard ratio 2.34 [95% CI 1.32-4.15]) and lifestyle (2.48 [1.45-4.22]) arms, but not in the metformin arm (0.55 [0.25-1.19]). CONCLUSIONS - Continuous antidepressant use was significantly associated with diabetes risk in the placebo and lifestyle arms. Measured confounders and mediators did not account for this association, which could represent a drug effect or reflect differences not assessed in this study between antidepressant users and nonusers.

Original languageEnglish (US)
Pages (from-to)2549-2551
Number of pages3
JournalDiabetes care
Issue number12
StatePublished - Dec 1 2010


ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this